Applications are invited from suitably qualified candidates for the post of a Research Clinician on the PROPEL trial. The PROPEL trial is a clinical vaccine trial which will investigate the potential value of maternal or neonatal vaccination with a pneumococcal conjugate vaccine (Prevenar13) in preventing pneumococcal carriage (as a surrogate for pneumococcal disease) in the first 20 weeks of life. The trial will be conducted according to ICH-GCP and local and internationally applicable regulatory standards.
The post-holder will assist the Clinical Trial Co-ordinator in the coordination of all clinical trial activities at the field sites providing supervision and leadership to a very experienced field team. The post-holder will also provide clinical care to study participants (expectant mothers and their subsequent born infants) and will be responsible, under the leadership of the clinical trial coordinator and PI, for safety reporting Throughout the trial. Ability to work under pressure and a high degree of attention to detail is required. Clinical experience in pediatrics/neonates and/or obstetrics would also be highly desirable. Previous experience of clinical vaccine trials and/or of working to ICH-GCP standards would be an advantage.
- MBBS or equivalent.
- Experience of staff management.
- Excellent written and spoken English.
- Commitment to working in a multi-disciplinary team.
- Excellent interpersonal and verbal/written communication skills.
- A flexible and well-organized approach to work and an ability to meet deadlines.
- Attentiveness to detail.
- Excellent organizational skills.
- Willingness to be on-call and work outside the normal working hours.
- Excellent IT skills (Microsoft Word,Excel,Access)
The salary will be paid in grad 2 and will be dependent on qualifications and experience. The take home salary for research clinician 1 is 64, 734 dalasi per month. Candidate with FWACP part 2 will be appointed as Research Clinician 2 with a take home salary of 71,437 dalasi equivalent to $1,785 per month using the prevailing USD/dalasi exchange rate.